Lung Cancer Diagnostic and Screening Market

Global Lung Cancer Diagnostic and Screening Market Is Estimated To Witness High Growth Owing To Rising Incidence of Lung Cancer


The global Lung Cancer Diagnostic and Screening Market is estimated to be valued at US$ ,931.0 Mn in 2022 and is expected to exhibit a CAGR of 7.8% over the forecast period 2021-2028.

A) Market Overview:

Lung cancer is one of the leading causes of cancer-related deaths worldwide. It is characterized by the uncontrolled growth of abnormal cells in the lungs. Early detection and screening are crucial for improving the survival rates of patients. The market for lung cancer diagnostics and screening is driven by the increasing incidence of lung cancer globally. According to the American Cancer Society, lung cancer accounts for about 13% of all new cancer cases and 25% of all cancer-related deaths in the United States. The rising prevalence of risk factors such as smoking, exposure to carcinogens, air pollution, and genetic predisposition is fueling the demand for effective diagnostic and screening tools.

B) Market Key Trends:

One key trend in the Lung Cancer Diagnostic and Screening Market Size is the increasing adoption of liquid biopsy tests. Liquid biopsy is a non-invasive method that allows for the detection of cancer-related genetic mutations, tumor DNA, and circulating tumor cells in the blood sample of a patient. It offers several advantages over traditional tissue biopsies, including minimal invasiveness, real-time monitoring of treatment response, and the ability to detect genetic alterations that may drive resistance to targeted therapies. Liquid biopsies are gaining popularity among healthcare professionals for their potential to revolutionize cancer diagnosis and monitoring.

For example, Guardant Health, a leading player in the liquid biopsy market, offers the Guardant360 test that uses next-generation sequencing technology to detect actionable mutations in solid tumors, including lung cancer. The test has shown promising results in clinical studies and has been widely adopted by oncologists for guiding treatment decisions in lung cancer patients.

C) PEST Analysis:

Political: Governments across the globe are implementing stringent regulations to control smoking and reduce exposure to carcinogens. For instance, the World Health Organization (WHO) has initiated the Framework Convention on Tobacco Control (FCTC) to reduce tobacco consumption and prevent lung cancer.

Economic: The economic burden of lung cancer is significant, both at the individual and societal levels. The high cost of treatment, coupled with productivity losses due to illness and premature death, poses a major economic challenge.

Social: Increasing awareness about the importance of early detection and screening for lung cancer is driving the demand for diagnostic and screening products. Educational campaigns, community outreach programs, and public health initiatives are playing a key role in promoting lung cancer screening.

Technological: Advances in technology have led to the development of innovative diagnostic tools, such as liquid biopsies, molecular profiling assays, and imaging techniques. These technologies are improving the accuracy and efficiency of lung cancer diagnosis and screening.

D) Key Takeaways:

Paragraph 1: The global Lung Cancer Diagnostic and Screening Market is expected to witness high growth, exhibiting a CAGR of 7.8% over the forecast period, due to increasing incidence of lung cancer. The rising prevalence of risk factors, such as smoking and exposure to carcinogens, is driving the demand for effective diagnostic and screening tools.

Paragraph 2: North America is expected to dominate the global market for lung cancer diagnostics and screening, owing to the high prevalence of lung cancer in the region and the availability of advanced healthcare infrastructure. Asia Pacific is anticipated to be the fastest-growing region, driven by increasing awareness, improving healthcare infrastructure, and a rising geriatric population.

Paragraph 3: Key players operating in the global Lung Cancer Diagnostic and Screening Market include Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc. These companies are focusing on strategic collaborations, product launches, and mergers and acquisitions to strengthen their market position and expand their product offerings.

In conclusion, the global Lung Cancer Diagnostic and Screening Market is poised for significant growth in the coming years. The increasing incidence of lung cancer, coupled with technological advancements in diagnostic tools, is driving the demand for effective screening and early detection methods. Liquid biopsy tests, in particular, are emerging as a game-changer in the field of cancer diagnosis and monitoring. With ongoing research and development efforts and the introduction of innovative products, the market is expected to witness continuous advancements and improvements in lung cancer diagnostics and screening.